Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.
about
Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In VitroBosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes.Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-GlucuronidePhase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.Effect of honokiol on the induction of drug-metabolizing enzymes in human hepatocytesRifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats.Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) EnzymesRifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.Advances in Drug Discovery and Development for Pediatric Tuberculosis.Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.Pharmacologic considerations in use and development of antituberculosis drugs.Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.Rifapentine for the treatment of latent tuberculosis.Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In VitroIn Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.Effects of anthocyans on the expression of organic anion transporting polypeptides (SLCOs/OATPs) in primary human hepatocytes.Effects of danshen ethanol extract on the pharmacokinetics of fexofenadine in healthy volunteers.Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?Suppression of miR-628-3p and miR-641 is involved in rifampin-mediated CYP3A4 induction in HepaRG cells.The Underrated Risks of Tamoxifen Drug Interactions.Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
P2860
Q28552429-136CCA6D-F2C7-415E-9C73-F9DD7F6178A1Q33655897-B7D14E98-69A4-48C1-8263-503D3FD679E6Q33797986-88C2596B-AD5B-45F1-9076-6DB7FF7241ACQ33891564-DE22D8F1-2DE1-4AA4-BF7D-4D3CE782D179Q34057466-183791E6-6701-4EB9-A139-827E45203577Q34470980-CF6BDCF4-7698-4287-B10B-5628193CA586Q35167188-869BCFBE-21B7-4609-B8DB-B603B8B9F3D6Q35974112-25791948-A0CD-46C3-BAD4-1251ED6AE978Q36338109-2609F0D1-E2AD-45BA-8E1B-E41D655C49C2Q36835708-1A02CFAC-F8A8-4A44-BA3C-7D235776E968Q37134041-1BAEC42E-9341-452C-B5F9-21AE32282A9BQ38207924-76AD3BC8-779F-4379-8C99-2D90BF7599E9Q38252559-F96634BA-1110-48D1-B11C-14B1BB68D349Q38634986-41FCF032-4D0D-47D2-8C83-D673530D9301Q38874266-B61AA938-611F-401A-80D3-C3E8829D246DQ38933165-6DBF5397-9FFE-47EB-8B6D-AA962B84F2E9Q38963389-A47F4091-FA00-4B11-8D2E-D4CD2E6F3CE0Q40441723-1E87C294-4415-4473-9AA0-0B1B0C354D27Q41595989-B1BBF3C8-2E9A-4060-BA29-850523BA12CBQ42105419-E4CAE1D0-A2A1-4117-9D27-43A6282CD503Q42688154-A87623F4-54D1-45ED-AD6F-B9060A19D30FQ51266624-30BD31DB-D744-478E-9497-65011FF59948Q52325476-80D5A399-27FA-4F2B-BB84-BFF7824BED44Q53109204-1B9FC4EC-5FF1-4048-B349-BFB1D851F7B8
P2860
Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Induction of influx and efflux ...... n, rifabutin, and rifapentine.
@en
Induction of influx and efflux ...... n, rifabutin, and rifapentine.
@nl
type
label
Induction of influx and efflux ...... n, rifabutin, and rifapentine.
@en
Induction of influx and efflux ...... n, rifabutin, and rifapentine.
@nl
prefLabel
Induction of influx and efflux ...... n, rifabutin, and rifapentine.
@en
Induction of influx and efflux ...... n, rifabutin, and rifapentine.
@nl
P2093
P2860
P356
P1476
Induction of influx and efflux ...... n, rifabutin, and rifapentine.
@en
P2093
Beth Williamson
David J Back
Kelly E Dooley
Yuan Zhang
P2860
P304
P356
10.1128/AAC.01124-13
P407
P50
P577
2013-09-23T00:00:00Z